HEPTAVAX-B IN PEDIATRIC DIALYSIS PATIENTS - EFFECT OF SYSTEMIC LUPUS-ERYTHEMATOSUS

被引：11

作者：

MOXEYMIMS, MM

PRESTON, K

FIVUSH, B

MCCURDY, F

机构：

[1] Children's Hospital National Medical Center, Washington, DC

[2] Johns Hopkins University Hospital, Baltimore, Maryland

[3] Uniformed Services University for the Health Sciences, Bethesda, Maryland

来源：

PEDIATRIC NEPHROLOGY | 1990年 / 4卷 / 02期

关键词：

Corticosteroids; Hemodialysis; Hepatavax-B; Peritoneal dialysis; Systemic lupus erythematosus;

D O I：

10.1007/BF00858834

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Twenty-three pediatric dialysis patients 16 hemodialysis (HD) and 17 peritoneal dialysis (PD)], with a mean age of 13.9 years, were vaccinated against hepatitis B virus and their seroconversion rates were analyzed. There was no significant difference in the mean duration of dialysis between the HD and PD groups, or between responders and nonresponders to the vaccine. In the HD group, there was a response rate of 83.3% while the PD patients had a response rate of 88.2%. The only patients failing to seroconvert after the three vaccine series all had systemic lupus erythematosus and were taking oral corticosteroids. © 1990 IPNA.

引用

页码：171 / 173

页数：3

共 12 条

[1]

Nivet H., Drucker J., Dubois F., Goudeau A., Coursaget P., Rolland J.C., Grenier B., Maupas P., Vaccine against hepatitis B in children: prevention of hepatitis in a pediatric hemodialysis unit, Int J Pediatr Nephrol, 3, pp. 25-28, (1982)

[2]

Callis L.M., Clanxet J., Fortuny G., Caballeria J., Carrasco J.L., Lardinois R., Hepatitis B virus infection and vaccination in children undergoing hemodialysis, Acta Paediatr Scand, 74, pp. 213-218, (1985)

[3]

Stevens C.E., Alter H.J., Taylor P.E., Zang E.A., Harley E.J., Hepatitis B vaccine in patients receiving hemodialysis —immunogenicity and efficacy, N Engl J Med, 311, pp. 496-501, (1984)

[4]

Recommendations for protection against viral hepatitis, MMWR, 34, pp. 313-335, (1985)

[5]

Jarrett M.P., Schiffman G., Barland P., Grayzel A.I., Impaired response to pneumococcal vaccine in systemic lupus erythematosus, Arthritis Rheum, 23, pp. 1287-1293, (1980)

[6]

Nies K., Boyer R., Stevens R., Louie J., Anti-tetanus toxoid antibody synthesis after booster immunization in systemic lupus erythematosus, Arthritis Rheum, 23, pp. 1343-1350, (1980)

[7]

Pelton B.K., Denman A.M., Defective B cell function in systemic lupus erythematosus, Clin Exp Immunol, 48, pp. 513-518, (1982)

[8]

Kallenberg C.G.M., Limburg P.C., Von Slochteren C., Van der Woude F.J., The T.H., B cell activity in systemic lupus erythematosus: depressed in vivo humoral immune response to a primary antigen (haemocyanin) and increased in vitro spontaneous immunoglobulin synthesis, Clin Exp Immunol, 53, pp. 371-383, (1983)

[9]

Turner-Stokes L., Cambridge G., Corcoran T., Oxford J.S., Snaith M.L., In vitro response to influenza immunization by peripheral blood mononuclear cells from patients with systemic lupus erythematosus and other autoimmune disease, Ann Rheum Dis, 47, pp. 532-535, (1988)

[10]

Brodman R., Gilfillan R., Glass D., Schur P.H., Influenzal vaccine response in systemic lupus erythematosus, Ann Intern Med, 88, pp. 735-740, (1978)

← 1 2 →